{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:11:43Z","timestamp":1758946303091,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"First Affiliated Hospital, Sun Yat-sen Universtiy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10557-018-6826-6","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:40:01Z","timestamp":1536108001000},"page":"581-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS)"],"prefix":"10.1007","volume":"32","author":[{"given":"Jianning","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijia","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-765X","authenticated-orcid":false,"given":"Jun","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"6826_CR1","volume-title":"Report on cardiovascular diseases in China 2017","author":"National Center for Cardiovascular Diseases C","year":"2017","unstructured":"National Center for Cardiovascular Diseases C. Report on cardiovascular diseases in China 2017. Beijing: Encyclopedia of China Publishing House; 2017."},{"issue":"2","key":"6826_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40256-017-0213-8","volume":"17","author":"SM Hoy","year":"2017","unstructured":"Hoy SM. Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017;17(2):157\u201368.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"6826_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/HYPERTENSIONAHA.108.120584","volume":"53","author":"T Kushiro","year":"2009","unstructured":"Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study. Hypertension. 2009;53(2):135\u201341.","journal-title":"Hypertension"},{"issue":"21","key":"6826_CR4","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"5","key":"6826_CR5","first-page":"447","volume":"3","author":"PM Ridker","year":"2010","unstructured":"Ridker PM, MacFadyen JG, Nordestgaard BG, Koenig W, Kastelein JJP, Genest J, et al. Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for \"Intermediate Risk\". Circ: Cardiovasc Qual Outcomes. 2010;3(5):447\u201352.","journal-title":"Circ: Cardiovasc Qual Outcomes"},{"issue":"19","key":"6826_CR6","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1161\/CIRCULATIONAHA.115.016759","volume":"132","author":"R Baudrand","year":"2015","unstructured":"Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vohringer PA, Jeunemaitre X, et al. Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. Circulation. 2015;132(19):1825\u201333.","journal-title":"Circulation"},{"issue":"12","key":"6826_CR7","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1253\/circj.CJ-12-0722","volume":"76","author":"S Warita","year":"2012","unstructured":"Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years\u2019 follow-up. Circ J. 2012;76(12):2755\u201362.","journal-title":"Circ J"},{"issue":"6","key":"6826_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/10641961003628460","volume":"32","author":"M Yoshika","year":"2010","unstructured":"Yoshika M, Komiyama Y, Masuda M, Yokoi T, Masaki H, Ohkura H, et al. Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists. Clin Exp Hypertens. 2010;32(6):341\u20136.","journal-title":"Clin Exp Hypertens"},{"issue":"24","key":"6826_CR9","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556\u201364.","journal-title":"JAMA"},{"issue":"8","key":"6826_CR10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","volume":"111","author":"EP Navarese","year":"2013","unstructured":"Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123\u201330.","journal-title":"Am J Cardiol"},{"issue":"5","key":"6826_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1586\/erc.11.47","volume":"9","author":"K Yokote","year":"2011","unstructured":"Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9(5):555\u201362.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"6826_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jdi.12483","volume":"7","author":"CH Huang","year":"2016","unstructured":"Huang CH, Huang YY, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig. 2016;7(5):769\u201376.","journal-title":"J Diabetes Investig"},{"issue":"11","key":"6826_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1463-1326.2011.01477.x","volume":"13","author":"J Gumprecht","year":"2011","unstructured":"Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6826_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/cen.12580","volume":"82","author":"SH Choi","year":"2015","unstructured":"Choi SH, Lim S, Hong ES, Seo JA, Park CY, Noh JH, et al. PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol. 2015;82(5):670\u20137.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"6826_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.metabol.2014.09.008","volume":"64","author":"Y Cho","year":"2015","unstructured":"Cho Y, Choe E, Lee YH, Seo JW, Choi Y, Yun Y, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism. 2015;64(4):482\u20138.","journal-title":"Metabolism"},{"key":"6826_CR16","unstructured":"Inc P-DDoP. Full prescribing information for LIPITOR. 2017. \n                    http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=587\n                    \n                  ."},{"key":"6826_CR17","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"issue":"3","key":"6826_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"6826_CR19","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"Suppl 1","key":"6826_CR20","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc17-S005","volume":"40","author":"Association. AD","year":"2017","unstructured":"Association. AD. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(Suppl 1):S11\u2013s24.","journal-title":"Diabetes Care"},{"key":"6826_CR21","first-page":"e13","volume":"71","author":"PK Whelton","year":"2017","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Hypertension. 2017;71:e13\u2013e115.","journal-title":"Hypertension"},{"issue":"10","key":"6826_CR22","first-page":"937","volume":"31","author":"Joint Committee of Chinese Guidelines for the Prevention and treatment of dyslipidemias in adults","year":"2016","unstructured":"Joint Committee of Chinese Guidelines for the Prevention and treatment of dyslipidemias in adults. A guideline for the prevention and treatment of dyslipidemias in Chinese adults (2016). Chin Circul J. 2016;31(10):937\u201353.","journal-title":"Chin Circul J"},{"issue":"5","key":"6826_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5551\/jat.E562","volume":"15","author":"T Yamakawa","year":"2008","unstructured":"Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15(5):269\u201375.","journal-title":"J Atheroscler Thromb"},{"issue":"46","key":"6826_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005429","volume":"95","author":"D Yoon","year":"2016","unstructured":"Yoon D, Sheen SS, Lee S, Choi YJ, Park RW, Lim HS. Statins and risk for new-onset diabetes mellitus: a real-world cohort study using a clinical research database. Medicine (Baltimore). 2016;95(46):e5429.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"6826_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00125-015-3802-6","volume":"59","author":"SJ Livingstone","year":"2016","unstructured":"Livingstone SJ, Looker HC, Akbar T, Betteridge DJ, Durrington PN, Hitman GA, et al. Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the collaborative atorvastatin in diabetes trial (CARDS). Diabetologia. 2016;59(2):299\u2013306.","journal-title":"Diabetologia"},{"issue":"8","key":"6826_CR26","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.clinthera.2014.06.009","volume":"36","author":"CA Sponseller","year":"2014","unstructured":"Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014;36(8):1211\u201322.","journal-title":"Clin Ther"},{"key":"6826_CR27","unstructured":"Yasuo Terauchi TY, J Kishimoto, C Ito, Mitsuhiko Noda, Masato Odawara, Teruo Shiba, Hiroji Kitazato, Koji Maemura, Kazuyuki Tobe, Yasuhiko Iwamoto, Yasuo Akanuma, Takashi Kadowaki, The J-Predict Study Investigators. Differential impact of pitavastatin on the incidence of diabetes in patients with or without hypertension: sub-analysis of J-PREDICT [abstract no. 1052-P]. In: 74th annual scientific sessions of the American Diabetes Association. 2014."},{"key":"6826_CR28","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.2147\/DDDT.S87979","volume":"9","author":"W Zhao","year":"2015","unstructured":"Zhao W, Zhao SP. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug Des Devel Ther. 2015;9:6211\u201323.","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"6826_CR29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.5551\/jat.29520","volume":"22","author":"A Nakagomi","year":"2015","unstructured":"Nakagomi A, Shibui T, Kohashi K, Kosugi M, Kusama Y, Atarashi H, et al. Differential effects of atorvastatin and pitavastatin on inflammation, insulin resistance, and the carotid intima-media thickness in patients with dyslipidemia. J Atheroscler Thromb. 2015;22(11):1158\u201371.","journal-title":"J Atheroscler Thromb"},{"key":"6826_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1567-5688(14)70002-9","volume":"16","author":"L Arnaboldi","year":"2015","unstructured":"Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015;16:1\u201327.","journal-title":"Atheroscler Suppl"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6826-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6826-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6826-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:13:32Z","timestamp":1567624412000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6826-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["6826"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6826-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"5 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This study has been approved by the Hospital\/University Ethics Committee (Clinical Research Ethics Committee at the First Affiliated Hospital of Sun Yat-sen University, Via Zhongshan 2nd road no.58, Guangzhou, China) and is compliant with the Declaration of Helsinki (1964) and its amendments.Informed consent is required for all enrollees in CAMPUS. Informed consent will be obtained by trained CAMPUS physicians, who will provide detailed explanations about CAMPUS to the participants. The participants are informed that participation in CAMPUS is voluntary, and withdrawal from the trial will not result in loss of benefit or differential treatment outside the trial. The participants will be asked questions to test their understanding about the trial and will be given adequate time to decide if they wished to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}}]}}